newsfilter
← Latest News
GlobeNewswire·

Ascentage Pharma to Participate in the Evercore 2nd Annual China Biotech Summit

  • Ascentage Pharma Group International will participate in the Evercore ISI 2nd Annual China Biotech Summit held August 17-19, 2026, at The Ritz-Carlton Shanghai, Pudong.
  • Management will join a fireside chat on August 18, 2026, from 7:45-8:00 am Beijing Time in Grand Ballroom 2 & 3, along with one-on-one investor meetings.
  • The company is a global, commercial-stage biopharmaceutical firm developing novel therapies for unmet cancer needs, with a pipeline including Bcl-2 inhibitors, MDM2-p53 inhibitors, kinase inhibitors, & protein degraders.
  • Olverembatinib, a third-generation BCR-ABL1 inhibitor approved in China, is covered by the National Reimbursement Drug List & is undergoing Phase III trials POLARIS-1, POLARIS-2, & POLARIS-3 for CML, Ph+ ALL, & SDH-deficient GIST respectively.
  • Lisaftoclax, a Bcl-2 inhibitor approved by China's NMPA for CLL/SLL, is currently in four global Phase III trials: GLORA, GLORA-2, GLORA-3, & GLORA-4 for various hematologic malignancies.
  • Ascentage Pharma holds global intellectual property rights & maintains partnerships with Takeda, AstraZeneca, Merck, Pfizer, Innovent, & research institutions like Dana-Farber, Mayo Clinic, National Cancer Institute, & University of Michigan.
  • The press release includes forward-looking statements subject to risks & uncertainties detailed in the company's SEC filings, including its 2025 Form 20-F & 2019 IPO prospectus.